Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

TP53 multihit

  • Home
  • TP53 multihit
TP53 Multihit Does Not Fully Erase the Prognostic Advantage of Isolated del(5q) in Myelodysplastic Neoplasms
Posted inHematology-Oncology news Pathology & Lab Medicine/Bệnh học

TP53 Multihit Does Not Fully Erase the Prognostic Advantage of Isolated del(5q) in Myelodysplastic Neoplasms

Posted by MedXY By MedXY 05/09/2026
A multicenter retrospective study suggests that MDS with isolated del(5q) and TP53 multihit alterations has substantially better survival than other low-blast TP53-multihit MDS, challenging how this subgroup should be classified.
Read More
  • Team Behavior and Patient Outcome Changes Following Human Factors Training in Pediatric Airway Endoscopy: A Review of Evidence and Clinical Implications
  • Longitudinal Voice Changes in Transmasculine Adolescents and Young Adults Undergoing Testosterone Therapy: Insights from a Prospective Cohort Study
  • Expedited Discharge After Isolated Coronary Artery Bypass Grafting: Impacts on Hospital Stay and Patient Outcomes
  • Genomic Profiling of Primary Gastric Tumors Predicts Recurrence Patterns and Survival Outcomes
  • Robotic Whole-Graft Liver Transplantation: Insights from 45 Cases and Benchmark Outcome Analysis
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology health heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health metformin Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prostate cancer public health quality of life randomized clinical trial randomized controlled trial randomized trial risk stratification SGLT2 inhibitors stroke type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in